Die neue Variante der Creutzfeldt-Jakob-Krankheit[¹]

Literatur

• 1 Brown P. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease.  BMJ. 2001;  322 841-844
• 2 Brown P, Will R G, Bradley R, Asher D M, Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns.  Emerg Infect Dis. 2001;  7 6-16
• 3 Bruce M E, McConnell I, Will R G, Ironside J W. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues.  Lancet. 2001;  358 208-209
• 4 Bruce M E, Will R G, Ironside J W, Fraser H. Der Zusammenhang zwischen der neuen CJD-Variante und der BSE. I. Berlin: de Gruyter In: Hörnlimann B, Riesner D, Kretzschmar HA. Prionen und Prionkrankheiten 2001: 435-439
• 5 Bryant G, Monk P. Summary of the final report of the investigation into the North Leicestershire cluster of variant Creutzfeldt-Jakob disease. Leicestershire NHS Health Authority http://www.leics-ha.org.uk (March 22, 2001) 2001
• 6 Cousens S, Smith P G, Ward H. et al . Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994 - 2000.  Lancet. 2001;  357 1002-1007
• 7 Goldwater P N. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: implications for Australia.  Med J Australia. 2001;  175 154-159
• 8 Green A JE, Thompson E J, Stewart G E. et al . Use of 14 - 3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease.  J Neurol Neurosurg Psychiatry. 2001;  70 744-748
• 9 Hilton D A, Fathers E, Edwards P, Ironside J W, Zajicek J. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease (letter).  Lancet. 1998;  352 703-704
• 10 Ironside J W, Hilton D A, Ghani A. et al . Retrospective study of prion-protein accumulation in tonsil and appendix tissues.  Lancet. 2000;  355 1693-1694
• 11 Korth C, May B C, Cohen F E, Prusiner S B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.  Proc Natl Acad Sci USA. 2001;  98 9836-9841
• 12 Lasmezas C I, Fournier J G, Nouvel V. et al . Adaptation of the bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt-Jakob disease: implications for human health.  Proc Natl Acad Sci USA. 2001;  98 4142-4147
• 13 Peretz D, Williamson R A, Kaneko K. et al . Antibodies inhibit prion propagation and clear cell cultures of prion infectivity.  Nature. 2001;  412 739-743
• 14 Scott M R, Will R, Ironside J. et al . Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans.  Proc Natl Acad Sci USA. 1999;  96 15 137-15 142
• 15 Simon D, Pauli G. Krankenversorgung und Instrumentensterilisation bei CJK-Patienten und CJK-Verdachtsfällen.  Bundesgesundhbl. 1998;  41 279-285
• 16 Verity C M, Nicoll A, Will R G, Devereux G, Stellitano L. Variant Creutzfeldt-Jakob disease in UK children: a national surveillance study.  Lancet. 2000;  356 1224-1227
• 17 Wadsworth J DF, Joiner S, Hill A F. et al . Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay.  Lancet. 2001;  358 171-180
• 18 Will R G. The transmission of prions to humans.  Acta Paediatr. 1999;  88 28-32 (Suppl))
• 19 Will R G. Portrait der neuen Variante der Creutzfeldt-Jakob-Krankheit (nvCJD). Berlin: de Gruyter In: Hörnlimann B, Riesner D, Kretzschmar HA. Prionen und Prionkrankheiten 2001: 151-157
• 20 Will R G, Ironside J W, Zeidler M. et al . A new variant of Creutzfeldt-Jakob disease in the UK.  Lancet. 1996;  347 921-925
• 21 Will R G, Zeidler M, Stewart G E. et al . Diagnosis of new variant Creutzfeldt-Jakob disease.  Ann Neurol. 2000;  47 575-582
• 22 Zeidler M, Sellar R J, Collie D A. et al . The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease.  Lancet. 2000;  355 1412-1418

1 Die Studie »Untersuchungen zur Epidemiologie, Frühdiagnose und molekularen Pathologie humaner spongiformer Enzephalopathien« läuft seit 1993 mit finanzieller Unterstützung des Bundesministeriums für Gesundheit und wird fortgeführt (Az 325-4471-02/15).

Korrespondenz